Benchmarking Maintenance Therapy Survival in First-Line Platinum-Based Chemotherapy–Treated Patients with Advanced Urothelial Carcinoma Using Simulated Disease Modeling

Autor: Galsky MD, Wirtz HS, Bloudek B, Hepp Z, Farrar M, Timmons J, Lenero E, Powles T

Publikováno v: Clinical Epidemiology, Vol Volume 15, Pp 765-773 (2023)

Matthew D Galsky,1 Heidi S Wirtz,2 Brian Bloudek,3 Zsolt Hepp,2 Mallory Farrar,2 Jack Timmons,3 Enrique Lenero,4 Thomas Powles5 1Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA; 2Seagen Inc., Bothell, WA, USA; 3Curt

Externí odkaz: https://doaj.org/article/51f72ee1f82c4a8a8b39d1c679df8e62

Estimated impact of ECHELON-1 overall survival on productivity costs in stage III/IV classical Hodgkin lymphoma in the United States.

Autor: Phillips T; Department of Hematology, City of Hope Medical Center, Duarte, CA., Liu N; Seagen Inc., Bothell, WA., Bloudek B; Curta, Inc., Seattle, WA., Migliaccio-Walle K; Curta, Inc., Seattle, WA., Reynolds J; Curta, Inc., Seattle, WA., Burke JM; US Oncology Hematology Research Program, Rocky Mountain Cancer Centers, Aurora, CO.

Publikováno v: Journal of managed care & specialty pharmacy [J Manag Care Spec Pharm] 2023 Dec; Vol. 29 (12), pp. 1312-1320. Date of Electronic Publication: 2023 Nov 03.

Estimating long-term progression-free and overall survival in patients with peripheral T-cell lymphoma: A US population-based oncology simulation model based on 5-year results from the ECHELON-2 trial.

Autor: Burke JM; US Oncology Hematology Research Program, Rocky Mountain Cancer Centers, Aurora, CO., Yu KS; Seagen Inc., Bothell, WA., Mordi U; Curta, Inc., Seattle, WA.; Bristol Myers Squibb, Princeton, NJ., Bloudek B; Curta, Inc., Seattle, WA., Liu N; Seagen Inc., Bothell, WA., Phillips T; Department of Internal Medicine, Division of Hematology and Oncology, University of Michigan Medical School, Ann Arbor, now with Department of Hematology, City of Hope Medical Center, Duarte, CA.

Publikováno v: Journal of managed care & specialty pharmacy [J Manag Care Spec Pharm] 2023 Mar; Vol. 29 (3), pp. 314-323.

CO68 Simulated mOS of Gemcitabine+Carboplatin ± Maintenance Avelumab Therapy or Enfortumab Vedotin + Pembrolizumab in First-Line Treatment of LA/mUC in Patients Ineligible for Cisplatin Using Disease Modeling

Autor: Galsky, M.D., Sonpavde, G.P., Bloudek, B., Farrar, M., Hepp, Z., Timmons, J., Powles, T.

Publikováno v: In Value in Health June 2023 26(6) Supplement:S26-S27

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.